PMC:4134656 / 14104-14810 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4134656","sourcedb":"PMC","sourceid":"4134656","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4134656","text":"Oral propranolol has three different pharmacological effects: Early, intermediate and long-term effects. The early effect of a visible change in colour and considerable softening of the lesion occurs within 1-3 days, after the initiation of therapy. This is related to the β2 inhibitory effect of propranolol that decreases the release of the vasodilator transmitters such as nitric oxide. The resulting vasoconstriction of the feeding capillaries is responsible for the early changes in haemangiomas. In view of its immediate clinical effect, propranolol is nowadays considered as the promising therapy in IH with ulceration or haemangiomas involving vital structures such as eyes, airways, genitalia etc.","tracks":[]}